Finally, a meta-analysis was conducted by Dai et al. evaluating the efficacy of GLP-1 RAs in patients with metabolic-associated fatty liver disease (MAFLD), reaching a conclusion that, regardless of T2D, GLP-1 RAs improve liver injury and metabolic disorder in patients with MAFLD [50]. Here, GCG is linked to metabolic disease.